Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ARANESP safely and effectively. See full prescribing information for ARANESP . ARANESP ® (darbepoetin alfa ) i njection, for intravenous or subcutaneous use Initial U.S. Approval: 2001
Medication labelWhy this: Advisory · dailymed-prescription
Aranesp is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis. Aranesp is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. Aranesp has not been shown to improve quality of life, fatigue, or patient well-being. Aranesp is not indicated for use: • In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. • In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. • In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. • As a substitute for RBC transfusions in patients who require immediate correction of anemia.
- generic_name
- darbepoetin alfa
- product_names
- darbepoetin alfa
- ndc
- 55513-098, 55513-098-01, 55513-098-04, 55513-006, 55513-006-01, 55513-006-21, 55513-002, 55513-002-01, 55513-002-04, 55513-003, 55513-003-01, 55513-003-04, 55513-004, 55513-004-01, 55513-004-04, 55513-005, 55513-005-01, 55513-005-04, 55513-028, 55513-028-01, 55513-111, 55513-111-01, 55513-032, 55513-032-01, 55513-057, 55513-057-01, 55513-057-04, 55513-021, 55513-021-01, 55513-021-04, 55513-023, 55513-023-01, 55513-023-04, 55513-025, 55513-025-01, 55513-025-04, 55513-027, 55513-027-01, 55513-027-04
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en